The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

A Case Report of Giant Cell Arteritis Combined with Oculomotor Nerve Palsy

동안신경마비가 동반된 거대세포 동맥염 환자의 치료 경험 - 증례보고 -

  • Ryu, Young Bin (Neuro-pain Clinic, Department of Anesthesiology and Pain Medicine, College of Medicine, Ajou University) ;
  • Han, Kyung Ream (Neuro-pain Clinic, Department of Anesthesiology and Pain Medicine, College of Medicine, Ajou University) ;
  • Kim, Chan (Neuro-pain Clinic, Department of Anesthesiology and Pain Medicine, College of Medicine, Ajou University)
  • 류영빈 (아주대학교 의과대학 마취통증의학교실 신경통증클리닉) ;
  • 한경림 (아주대학교 의과대학 마취통증의학교실 신경통증클리닉) ;
  • 김찬 (아주대학교 의과대학 마취통증의학교실 신경통증클리닉)
  • Received : 2007.09.16
  • Accepted : 2007.11.20
  • Published : 2007.12.10
Download PDF
⟨ Previous Next ⟩

Abstract

Giant cell arteritis, which is also referred to as temporal arteritis, is defined as a systemic vasculitis in individuals over 50 years of age. Here, we report a case of giant cell arteritis combined with oculomotor nerve palsy. An 81-year old female patient experienced a headache for 10 days in her left temporoparietal area, that was characterized by a continuous dull ache and heaviness with intermittent shooting and lancinating pain. Her symptoms persisted in spite of receiving strong analgesics in another hospital. Upon physical examination, she was found to have marked tenderness over the left temporal area, especially along the path of the temporal artery as well as limitation of adduction, supraduction and infraduction of the left eyeball. At the time of admission, her erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were 52 mm/hr and 3.94 mg/dl. In addition her brain MRI revealed no specific findings. Giant cell arteritis was suspected based on the clinical symptoms and signs as well as the elevated ESR and CRP. Oral steroid therapy started was started with an initial dose of 40 mg of prednisolone per day that was gradually tapered to 5 mg a day for 2 weeks. Her headache subsided one day after the steroid therapy and oculomotor nerve palsy was markedly improved after 2 weeks of the therapy. After 2 months she had recovered completely from her symptoms.

Keywords

References

  1. Carroll SC, Gaskin BJ, Dancsh-Meyer HV: Giant cell arteritis. Clin Experiment Ophthalmol 2006; 34: 159-73 https://doi.org/10.1111/j.1442-9071.2006.01186.x
  2. Paraskevas KI, Boumpas DT, Vrentzos GE, Mikhailidis DP: Oral and ocular/orbital manifestations of temporal arteritis: a disease with deceptive clinical symptoms and devastating consequences. Clin Rheumatol 2007: 26; 1044-8 https://doi.org/10.1007/s10067-006-0493-x
  3. Gonzalez-Gay MA. Lopez-Diaz MJ, Barros S, Garcia- Porrua C, Sanchez-Andrade A, Paz-Carreira J, et al: Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore) 2005: 84: 277-90 https://doi.org/10.1097/01.md.0000180043.19285.54
  4. Bhatti MT, Tabandeh H: Giant cell arte ritis : diagnosis and management. Curr Opin Ophthahnol 2001; 12: 393-9 https://doi.org/10.1097/00055735-200112000-00003
  5. Rahman W, Rahman FZ: Giant cell (temporal) arteritis: an overview and update. Surv Ophthalmol 2005; 50: 415-28 https://doi.org/10.1016/j.survophthal.2005.06.011
  6. Fertaccioli OF, Di Poi E, Damato R: Steroid sparing therapeutic approaches to polymyalgia rhcumatica -glant cell aneritis. State of the an and perspectives. Clin Exp Rheumatol 2000; 18: 58-60
  7. Drchmer TJ, Khanna D, Marken RJ. Hawkins RA: Diagnostic and management trends of giant cell arterit is: a physician survey. J Rhcumatol 2005; 32: 1283-9
  8. Hayrch SS, Zimmerman B: Visual deterioration in giant cell arteritis patients white on high doses of cortlcosreroid therapy. Ophthalmology 2003; 110: 1204-15 https://doi.org/10.1016/S0161-6420(03)00228-8
  9. Lincoff NS, Erlich PD, Brass LS: Thrombocytosis in temporal arteritis rising platelet counts: a red flag for giant cell arteritis. J Neuroophthalmol 2000; 20: 67-72 https://doi.org/10.1097/00041327-200020020-00001
  10. Hayrch SS, Zimmerman B: Managament of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophtha lmologica 2003; 217: 239-59 https://doi.org/10.1159/000070631
  11. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al: The American College of Rheumatology 1990 criteria for the classiflcation of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-8 https://doi.org/10.1002/art.1780330810
  12. Gurwood AS, Malloy KA: Giant cell aneritis. Clin Exp Optom 2002; 85: 19-26 https://doi.org/10.1111/j.1444-0938.2002.tb03068.x
  13. Park SY, Han KR, Clio WD, Lee SH, Kim C: A case repcn of temporal aneritis. Korean J Anesthesiol 2003; 44: 138-41 https://doi.org/10.4097/kjae.2003.44.1.138

Cited by

  1. 류마티스성 다발성 근육통의 치료 경험 -증례보고- vol.21, pp.3, 2007, https://doi.org/10.3344/kjp.2008.21.3.241
  2. A Case of Atypical Giant Cell Arteritis Presenting as Raynaud's Phenomenon and Diagnosed by Random Temporal Artery Biopsy vol.17, pp.3, 2007, https://doi.org/10.4078/jkra.2010.17.3.278